Dear AuntMinnie Member,
PET/CT performs well in evaluating soft-tissue sarcoma lesions, with the modality producing high sensitivity for both initial imaging and recurrence assessment.
Staff writer Wayne Forrest's story, featured today in our Molecular Imaging Digital Community, describes two studies that put PET/CT through its paces for soft-tissue sarcoma. The researchers assessed both diagnostic accuracy and the concordance between the PET and CT components of the exam.
First, Canadian researchers looked at PET/CT for both soft-tissue sarcoma and osseous sarcoma. They found that it produced average sensitivity of 93% for both types of cancer, with higher sensitivity for osseous sarcoma.
The article goes on to describe the work of a U.S. research team in a separate study designed to learn more about the discrepancies between PET and CT when evaluating treatment response and follow-up therapy in patients with soft-tissue sarcoma. While discrepancies occurred in 11% of cases, the two modalities working together in general were more accurate than either working alone. Get the rest of the details by clicking here.
A second story we're featuring in the community describes how PET can detect changes in brain function among young male alcohol abusers. The modality was able to detect differences between the test group and controls that weren't apparent on neuropsychological tests. Learn more by clicking here.
Get these stories and more news about molecular imaging in our Molecular Imaging Digital Community, at molecular.auntminnie.com.
